Liraglutide is a glucagon like peptide -1 (GLP-1) agonist, which is approved for use in patients with type 2 diabetes. Studies of liraglutide have shown an appetite suppressive effect and has been associated with weight loss in patients with type 2 diabetes. Liraglutide use in the treatment of PWS is limited to one case report by Cyganek et el (See attached Citation). In this case report, the subject showed improvements in hemoglobin A1c and body weight over 14 weeks. The investigators plan to examine the use of liraglutide in a single subject with Prader Willi Syndrome and type 2 diabetes for one year. The investigators will examine clinical parameters, clinical assessment of hunger, and biochemical markers of diabetes and lipid control.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
1
Liraglutide 0.6 mg SQ daily for one week, increase to a maximum dose of 1.8 mg SQ daily by 6 weeks, and subsequent continuation for the remainder of a year.
Vancouver General Hospital - Diamond Center
Vancouver, British Columbia, Canada
Hemoglobin A1C
Time frame: Change from baseline in A1C at 12 months
Fasting Blood Glucose (mmol/L)
Time frame: Change from baseline in fasting blood glucose at 12 months
Fasting Blood Insulin level
Time frame: Change from baseline in fasting blood insulin at 12 months
Body Weight (kg)
Time frame: Change from baseline in body weight at 12 months
Fasting Lipid Profile
Time frame: Change from baseline in fasting lipid profile at 12 months
Hip Circumference (cm)
Time frame: Change from baseline in hip circumference at 12 months
Total Body Adipose Tissue Distribution (whole body Computed Tomography)
Time frame: Change from baseline in total body adipose tissue distribution at 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.